Itulazax

Betula verrucosa, the active ingredient in Itulazax, is a allergen extract presented as a sublingual preparation for sublingual use. It treats allergic rhinitis and allergic conjunctivitis caused by birch pollen in patients with IgE‑mediated sensitivity.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Itulazax is used in allergy immunotherapy to address IgE‑mediated reactions to birch pollen.

Allergic rhinitis: reduces nasal congestion, sneezing and itching caused by Betula verrucosa pollen. Allergic conjunctivitis: alleviates eye redness, itching and tearing associated with birch pollen exposure. Seasonal allergic rhinoconjunctivitis: provides sustained symptom control throughout the birch pollen season.

Adverse reactions to Itulazax are generally related to local immune activation in the oral cavity and systemic allergic responses.

Common Side Effects: - Oral itching: mild irritation of the mouth or throat after dosing. - Throat irritation: transient discomfort in the throat. - Nasal congestion: temporary blockage of nasal passages.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Angioedema: swelling of lips, tongue or face. - Severe bronchospasm: acute narrowing of airways causing breathing difficulty.

When prescribing Itulazax, clinicians should consider several safety measures.

Patient selection: confirm IgE‑mediated Betula verrucosa allergy before initiating therapy. Initial dosing: start with a low sublingual dose under medical supervision. Monitoring: observe for at least 30 minutes after first administration for systemic reactions. Contraindications: avoid in patients with a history of severe anaphylaxis to birch pollen. Pregnancy and lactation: use only if potential benefit justifies potential risk; data limited. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and direct sunlight.

Itulazax may interact with other medications that affect allergic response or immune modulation.

Major Interactions (Avoid): - Concurrent use of beta‑blockers: may mask symptoms of anaphylaxis and complicate treatment. - ACE inhibitors: increase risk of angioedema during allergic reactions.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce efficacy of sublingual immunotherapy if taken shortly before dosing. - Corticosteroids: may alter immune response, requiring dose adjustment. - Other allergen extracts: simultaneous administration can increase risk of systemic reactions.